SPI-62 is under clinical development by Sparrow Pharmaceuticals and currently in Phase II for Cushing’s Syndrome. According to GlobalData, Phase II drugs for Cushing’s Syndrome have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SPI-62’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SPI-62 overview

Concomitant therapy of SPI-62 and next generation corticosteroid is under development for the treatment of cushing's syndrome, autonomous cortisol secretion, type 2 diabetes in obese patients and polymyalgia rheumatica (PMR). It is administered though oral route in the form of tablet and also administered through intraocular, topical routes. It acts by targeting 11 beta-hydroxysteroid dehydrogenase type 1 (HSD1). It was also under development for anterior uveitis, psoriasis, atopic dermatitis, giant cell arthritis and chronic obstructive pulmonary disease (COPD exacerbation)

Sparrow Pharmaceuticals overview

Sparrow Pharmaceuticals is a biopharmaceutical company. It develops novel drugs for the treatment of excess corticosteroid disorders including diabetes, heart diseases, bone fractures, depression, glaucoma, and others. The company is investigating its lead product candidate SPI-62, a proprietary HSD-1 inhibitor to treat endogenous Cushing’s syndrome and autonomous cortisol secretion. Sparrow Pharmaceuticals is also evaluating SPI-62 in combination with prednisolone, a corticosteroid medication against polymyalgia rheumatica. It was funded by OrbiMed Healthcare Fund Management, Rivervest and US Venture Partners. Sparrow Pharmaceuticals is headquartered in Portland, Oregon, the US.

For a complete picture of SPI-62’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.